- Home
- GLPG vs GOF Comparison
GLPG vs GOF Comparison
Compare GLPG & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLPG | GOF |
|---|---|---|
| Founded | 1999 | N/A |
| Country | Belgium | United States |
| Employees | 704 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | GLPG | GOF |
|---|---|---|
| Price | $33.70 | $11.83 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $36.50 | N/A |
| AVG Volume (30 Days) | 88.6K | ★ 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.59 | $11.68 |
| 52 Week High | $37.78 | $15.93 |
Technical Indicators
Market Signals| Indicator | GLPG | GOF |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 30.93 |
| Support Level | $31.88 | N/A |
| Resistance Level | $34.98 | $15.10 |
| Average True Range (ATR) | 0.76 | 0.15 |
| MACD | -0.09 | -0.03 |
| Stochastic Oscillator | 32.98 | 15.59 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.